APOA5 encodes a novel apolipoprotein (apo A-V) which appears to be a modulator of plasma triglyceride (TG). In apoA5 knock out mice plasma TG level increases almost fourfold, whereas in human APOA5 transgenic mice it decreases by 70%. Some SNPs in the APOA5 gene have been associated with variations in plasma TG in humans. In addition, hypertriglyceridaemic (HTG) patients have been identified who carried rare nonsense mutations in the APOA5 gene (Q139X and Q148X), predicted to result in apo A-V deficiency. In this study we report a 17-year-old male with high TG and low high density lipoprotein cholesterol (HDL-C), who at the age of two had been found to have severe HTG and eruptive xanthomas suggesting a chylomicronaemia syndrome. Plasma postheparin LPL activity, however, was normal and no mutations were found in LPL and APOC2 genes. The sequence of APOA5 gene revealed that the patient was homozygous for a point mutation (c.289 C>T) in exon 4, converting glutamine codon at position 97 into a termination codon (Q97X). Apo A-V was not detected in patient's plasma, indicating that he had complete apo A-V deficiency. The administration of a low-fat and low-oligosaccharide diet, either alone or supplemented with ω-3 fatty acids, started early in life, reduced plasma TG to a great extent but had a negligible effect on plasma HDL-C. Loss of function mutations of APOA5 gene may be the cause of severe HTG in patients without mutations in LPL and APOC2 genes.

Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene / PRIORE OLIVA, Claudio; Carubbi, Francesca; Schaap, F. G; Bertolini, S; CALANDRA BUONAURA, Sebastiano. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - STAMPA. - 263:4(2008), pp. 450-458. [10.1111/j.1365-2796.2007.01912.x]

Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene

PRIORE OLIVA, Claudio;CARUBBI, Francesca;CALANDRA BUONAURA, Sebastiano
2008

Abstract

APOA5 encodes a novel apolipoprotein (apo A-V) which appears to be a modulator of plasma triglyceride (TG). In apoA5 knock out mice plasma TG level increases almost fourfold, whereas in human APOA5 transgenic mice it decreases by 70%. Some SNPs in the APOA5 gene have been associated with variations in plasma TG in humans. In addition, hypertriglyceridaemic (HTG) patients have been identified who carried rare nonsense mutations in the APOA5 gene (Q139X and Q148X), predicted to result in apo A-V deficiency. In this study we report a 17-year-old male with high TG and low high density lipoprotein cholesterol (HDL-C), who at the age of two had been found to have severe HTG and eruptive xanthomas suggesting a chylomicronaemia syndrome. Plasma postheparin LPL activity, however, was normal and no mutations were found in LPL and APOC2 genes. The sequence of APOA5 gene revealed that the patient was homozygous for a point mutation (c.289 C>T) in exon 4, converting glutamine codon at position 97 into a termination codon (Q97X). Apo A-V was not detected in patient's plasma, indicating that he had complete apo A-V deficiency. The administration of a low-fat and low-oligosaccharide diet, either alone or supplemented with ω-3 fatty acids, started early in life, reduced plasma TG to a great extent but had a negligible effect on plasma HDL-C. Loss of function mutations of APOA5 gene may be the cause of severe HTG in patients without mutations in LPL and APOC2 genes.
263
4
450
458
Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene / PRIORE OLIVA, Claudio; Carubbi, Francesca; Schaap, F. G; Bertolini, S; CALANDRA BUONAURA, Sebastiano. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - STAMPA. - 263:4(2008), pp. 450-458. [10.1111/j.1365-2796.2007.01912.x]
PRIORE OLIVA, Claudio; Carubbi, Francesca; Schaap, F. G; Bertolini, S; CALANDRA BUONAURA, Sebastiano
File in questo prodotto:
File Dimensione Formato  
priore oliva 2008.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 262.27 kB
Formato Adobe PDF
262.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
j.1365-2796.2007.01912.x.pdf

embargo fino al 20/12/2009

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 251.15 kB
Formato Adobe PDF
251.15 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1063470
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 42
social impact